Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer - PubMed (original) (raw)
Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer
Jianya Zhou et al. Cancer Lett. 2017.
Abstract
KRAS is one of the most commonly mutated oncogenes in non-small cell lung cancer (NSCLC). Resistance to MEK inhibitor monotherapy develops through a variety of mechanisms. CDK4 was reported to have a synthetic lethal interaction with KRAS. In this study, we demonstrated the combination effects of the MEK inhibitor selumetinib and the CDK4/6 inhibitor palbociclib in RAS-driven NSCLC. In vitro, cell lines with CDKN2A mutations were insensitive to selumetinib. We used siRNA and pharmacologic inhibition of CDK4 and found that the combination of selumetinib and palbociclib synergistically inhibited RAS-driven NSCLC cases with CDKN2A mutations but not those with wild type CDKN2A. The combination treatment potentiated growth inhibition and increased the population of cells in G1 phase. Selumetinib completely inhibited p-ERK but not p-RB. The addition of palbociclib markedly inhibited p-RB and downregulated survivin expression. In vivo, the combination treatment inhibited the growth of NSCLC xenografts, which correlated with decreased levels of p-RB, downregulated survivin and decreased Ki-67 staining. These data suggest that the combination treatment of palbociclib and selumetinib is effective in preclinical models of RAS-driven NSCLC with CDKN2A mutations.
Keywords: CDK4/6; CDKN2A; MEK; RAS; Survivin.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
- Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z, Le Blanc JM, Wang C, Zhan T, Zhuang H, Wang P, Yuan Z, Lu B. Tao Z, et al. Clin Cancer Res. 2016 Jan 1;22(1):122-33. doi: 10.1158/1078-0432.CCR-15-0589. Clin Cancer Res. 2016. PMID: 26728409 - Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Lee MS, et al. Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153. Oncotarget. 2016. PMID: 27167191 Free PMC article. - RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB. Chen SH, et al. Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23. Oncogene. 2018. PMID: 29059158 - Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara G, Gridelli C. Casaluce F, et al. Expert Opin Investig Drugs. 2017 Aug;26(8):973-984. doi: 10.1080/13543784.2017.1351543. Epub 2017 Jul 12. Expert Opin Investig Drugs. 2017. PMID: 28675058 Review. - Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M, Assunta S, Antonio R, Claudia SP, Anna BM, Clorinda S, Francesca C, Fortunato C, Cesare G. Paolo M, et al. Rev Recent Clin Trials. 2013 Jun;8(2):93-100. doi: 10.2174/15748871113089990047. Rev Recent Clin Trials. 2013. PMID: 24063423 Review.
Cited by
- Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, Bohnenberger H, Knödler M, Kurreck A, Sulzer S, Beyer G, Dorman K, Fröhlich T, Hegenberg S, Lugnier C, Saborowski A, Vogel A, Lange S, Reichert M, Flade F, Klaas L, Utpatel K, Becker H, Bleckmann A, Wethmar K, Reinacher-Schick A, Westphalen CB. Witte D, et al. J Cancer Res Clin Oncol. 2024 Oct 1;150(10):438. doi: 10.1007/s00432-024-05954-5. J Cancer Res Clin Oncol. 2024. PMID: 39352477 Free PMC article. - Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells.
Bhutkar S, Yadav A, Patel H, Barot S, Patel K, Dukhande VV. Bhutkar S, et al. Cancers (Basel). 2024 Jul 30;16(15):2713. doi: 10.3390/cancers16152713. Cancers (Basel). 2024. PMID: 39123441 Free PMC article. - CDK4/6 inhibitors in lung cancer: current practice and future directions.
Lv S, Yang J, Lin J, Huang X, Zhao H, Zhao C, Yang L. Lv S, et al. Eur Respir Rev. 2024 Feb 14;33(171):230145. doi: 10.1183/16000617.0145-2023. Print 2024 Jan 31. Eur Respir Rev. 2024. PMID: 38355149 Free PMC article. Review. - A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
Tang H, Ge Y, You T, Li X, Wang Y, Cheng Y, Bai C. Tang H, et al. BMC Cancer. 2023 Oct 10;23(1):958. doi: 10.1186/s12885-023-11464-3. BMC Cancer. 2023. PMID: 37817078 Free PMC article. - Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K, Ling X, Jiang X, Ma J, Zhu J. Cao K, et al. Respir Res. 2022 Nov 10;23(1):306. doi: 10.1186/s12931-022-02226-z. Respir Res. 2022. PMID: 36357897 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous